In tumor-bearing mice, Bifidobacterium supplementation improved tumor control similarly to anti–PD-L1 immunotherapy, while combining Bifidobacterium supplementation and anti–PD-L1 therapy resulted in synergistic antitumor activity and an almost complete inhibition of in vivo tumor growth [142]. This evidence concerns the gene CD274 and neoplasm.